EPiC Auditors Awarded Top 5 Quality Assurance Services Companies in the UK

We are delighted to announce that EPiC Auditors have won a place in Pharma Tech Outlook’s Top 5 Quality Assurance Services Companies in the UK 2022, the annual listing of 5 companies in the UK that are at the forefront of providing Quality Assurance services and transforming businesses in the region.

Specialising in performing mock inspections, GXP audits, supply chain and system audits, delivering bespoke training and supporting post-inspection remediation EPiC Auditors help clients achieve and maintain regulatory compliance.

Comprising of an experienced group of ex-MHRA Inspectors, the EPiC management team and consultants fully understand clients’ diverse needs and can therefore advise the best course of action to address the challenges they face and make their operations compliant with MHRA and EU regulations and guidelines by providing comprehensive GXP consultancy service.

As ex MHRA inspectors, EPiC Auditors is able to bridge the gap between pharmaceutical companies and the regulatory bodies, making us ideally placed to provide the knowledge, skills and expertise to drive sustainable compliance across the UK and Europe’s pharmaceutical and biotechnology industries.

You can access the Pharma Tech Outlook Magazine Quality Assurance Edition and read the full feature article here: https://www.pharmatechoutlook.com/magazines/May2022/Quality_Assurance_Europe/?digitalmagazine

MHRA Inspectorate Blog has recently published Part 2 in the Compliance Monitor Process series with further information about the Compliance Monitor (CM) role and application process.

The blog can be found here: Compliance Monitor Process (Part 2)– CM role and application process

The blog acknowledges that it is common for companies that are at IAG to employ consultants to assist with remediation activities, and this is something that EPiC has extensive experience of supporting including reporting on progress to MHRA. The application process for an individual to apply for the CM pilot programme to be named on a register will be based on an eligibility assessment by MHRA considering career history, relevant experience, not having been personally the subject of MHRA regulatory action and/or significant adverse findings in the previous 3 years, and the need to have completed relevant training in the CM process. Eligible CM’s will then be assessed by MHRA for suitability on a case-by-case basis when they are nominated by a company, to confirm that they have sufficient experience of the dosage forms and site operations and that there is no conflict of interest. 

In response to the recent MHRA Inspectorate Blog post, Richard Andrews commented “It is good to see that both eligibility and suitability of the CM are being assessed which draws parallels from the naming of Qualified Persons (QPs) on UK manufacturing licences. Although a QPs eligibility to be named may be assessed by the Joint Professional Bodies, MHRA, or an EU regulator, their suitability to be named on a specific UK manufacturing licence is assessed and decided by MHRA based on site-specific knowledge and experience, which is above and beyond their eligibility assessment. The same two-stage approach will help to ensure CMs will have the background experience and site-specific knowledge to assess risks to product quality and patients in developing and overseeing remediation plans and assisting with implementation. This type of remediation work is a core service we offer at EPiC and is why our consultants will be applying to be named as CMs.”